FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to haematology, and can be used for prediction of arterial and venous thrombosis in patients with Ph-negative myeloproliferative neoplasms. Concentration of endothelial dysfunction marker in blood plasma is determined. As a marker of endothelial dysfunction, blood plasma content of soluble thrombomodulin is determined. If its content is more than or equal to 2.36 ng/ml, a probability of arterial and venous thrombosis in the patient is predicted.
EFFECT: method provides the possibility of predicting the risk of thromboembolic complications (arterial and venous thrombosis) in patients with Ph-negative myeloproliferative neoplasms, having normal von Willebrand factor values, by determining content of soluble thrombomodulin in blood plasma.
1 cl, 7 tbl, 7 ex
